Genetic Forms of Parkinson Disease May Hold Most Potential for Targeted Treatment

Parkinson's disease (PD) is caused by various complex factors, including genetics, lifestyle, and the environment, making it challenging to develop new treatments. Despite the complexity and the lack of significant progress in recent decades, current treatments mainly focus on managing symptoms rather than stopping or slowing the disease. Ignacio Mata, PhD, from the Cleveland Clinic Lerner Institute, emphasized the importance of early detection and the potential for targeted approaches in genetic forms of PD. He noted that PD is biologically and symptomatically complex, with over 20 genes linked to familial PD and around 100 genes identified as risk factors. Environmental and lifestyle factors add to this complexity. Existing treatments, like long-used drugs and surgical options such as deep brain stimulation, manage symptoms but do not halt disease progression. Most PD patients are diagnosed only after significant neuronal damage has occurred, often 10-20 years after the disease begins. This delay in diagnosis limits the effectiveness of current therapies. Mata suggested that early detection, potentially through biomarkers like α-synuclein aggregation, could identify patients before symptoms develop, allowing for earlier intervention. He also mentioned that ongoing clinical trials, especially those targeting genetic forms of PD, offer hope. These trials aim to slow or stop disease progression by understanding and compensating for specific biological deficits. In summary, there is a critical need for new therapies that not only manage symptoms but also slow or stop the progression of PD, with particular focus on early detection and targeted treatments for genetic forms of the disease.